For this reason, the CNS-specific mPFS and mOS we observe herein of 6 and 14.3 months, respectively, are overestimations of the outcomes seen in real-world studies of patients with HER2+ BC LM [38]. This evidence concerns the gene ERBB2 and breast cancer.